Adductor Spasmodic Dysphonia
7
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia
The 'Lombard Effect' in Patients Affected by Adductor Laryngeal Dystonia
Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
Effects of Vocal Exercises for Spasmodic Dysphonia
The Effect of Vocal Rest Versus Vocalization Following Xeomin® Injections in Spasmodic Dysphonia
Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges